HUP0200202A2 - Stabilis, nemvizes egyfázisú, viszkózus vivőanyagok és ilyen vivőanyagokat hasznosító összetételek - Google Patents

Stabilis, nemvizes egyfázisú, viszkózus vivőanyagok és ilyen vivőanyagokat hasznosító összetételek

Info

Publication number
HUP0200202A2
HUP0200202A2 HU0200202A HUP0200202A HUP0200202A2 HU P0200202 A2 HUP0200202 A2 HU P0200202A2 HU 0200202 A HU0200202 A HU 0200202A HU P0200202 A HUP0200202 A HU P0200202A HU P0200202 A2 HUP0200202 A2 HU P0200202A2
Authority
HU
Hungary
Prior art keywords
vehicles
preparations
single phase
stable non
aqueous single
Prior art date
Application number
HU0200202A
Other languages
English (en)
Inventor
Stephen A. Berry
Houdin Dehnad
Pamela J. Fereira
Anna Muchnik
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22382917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0200202(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of HUP0200202A2 publication Critical patent/HUP0200202A2/hu
Publication of HUP0200202A3 publication Critical patent/HUP0200202A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány stabilis, nemvizes egyfázisú, viszkózus vivőanyagokra,valamint ezeket a vivőanyagokat hasznosító összetételekre(készítményekre) vonatkozik. A találmány szerinti összetételeklegalább egy, a vivőanyagban egyenletesen szuszpendált kedvezőhatóanyagot tartalmaznak. A készítmények a jéghideg hőmérséklettőltesthőmérsékletig terjedő hőmérsékleteken hosszú időn át tárolhatók. Akészítmények a gyógyszer-hatóanyagadagoló (felszabadító) rendszerekbőlegyenletesen szabadíthatók fel; a rendszer kimeneténél a nyírásisebesség körülbelül 1-1 x 10-7 reciprok másodperc. Ó
HU0200202A 1999-02-08 2000-02-02 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles HUP0200202A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11917099P 1999-02-08 1999-02-08

Publications (2)

Publication Number Publication Date
HUP0200202A2 true HUP0200202A2 (hu) 2002-05-29
HUP0200202A3 HUP0200202A3 (en) 2009-08-28

Family

ID=22382917

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200202A HUP0200202A3 (en) 1999-02-08 2000-02-02 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

Country Status (22)

Country Link
EP (2) EP1152749B1 (hu)
JP (1) JP4861551B2 (hu)
KR (2) KR100858856B1 (hu)
CN (1) CN1232244C (hu)
AR (1) AR029613A1 (hu)
AT (2) ATE537811T1 (hu)
AU (1) AU775904B2 (hu)
CA (1) CA2361424C (hu)
CO (1) CO5140096A1 (hu)
CY (1) CY1119950T1 (hu)
DE (1) DE60027272T2 (hu)
DK (1) DK1666026T4 (hu)
ES (2) ES2379471T5 (hu)
HK (2) HK1041451B (hu)
HU (1) HUP0200202A3 (hu)
IL (1) IL144755A0 (hu)
NO (1) NO20013861L (hu)
NZ (1) NZ513441A (hu)
PT (2) PT1666026E (hu)
TW (2) TWI292716B (hu)
WO (1) WO2000045790A2 (hu)
ZA (1) ZA200106443B (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006512370A (ja) * 2002-12-19 2006-04-13 アルザ・コーポレーション 安定な非水性単相ゲル、および植込み型デバイスから送達するためのその配合物
TW200505500A (en) * 2003-03-31 2005-02-16 Alza Corp Non-aqueous single phase vehicles and formulations utilizing such vehicles
JP2006521897A (ja) 2003-03-31 2006-09-28 アルザ・コーポレーション 内部圧力を放散する手段を備える浸透ポンプ
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP2361630A1 (en) * 2005-02-03 2011-08-31 Intarcia Therapeutics, Inc Implantable drug delivery device comprising particles and an osmotic pump
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2376522A4 (en) 2008-11-16 2013-12-25 Univ Texas LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PT3192501T (pt) 2011-05-25 2020-07-31 Novaliq Gmbh Composição farmacêutica tópica à base de alcanos semifluorados
WO2012160180A2 (en) 2011-05-25 2012-11-29 Novaliq Gmbh Pharmaceutical composition for administration to nails
IN2014CN03555A (hu) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
BR112014017719A8 (pt) 2012-01-23 2017-07-11 Novaliq Gmbh Composições de proteína estabilizada baseadas em alcanos semifluorados
CN113679698B (zh) 2012-09-12 2022-07-26 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
PL3181119T3 (pl) 2012-09-12 2020-01-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki
AU2014295052B2 (en) 2013-07-23 2018-08-30 Novaliq Gmbh Stabilized antibody compositions
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
CN111743882A (zh) 2015-09-30 2020-10-09 诺瓦利克有限责任公司 半氟化化合物和其组合物
ES2803248T3 (es) 2015-09-30 2021-01-25 Novaliq Gmbh 2-perfluorohexil octano para administración oftálmica
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
CA3036306C (en) 2016-09-23 2024-05-14 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN110678207B (zh) 2017-04-21 2024-08-02 德马利克治疗公司 碘组合物
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
PL3856128T3 (pl) 2018-09-27 2023-10-16 Dermaliq Therapeutics, Inc. Formulacja filtra przeciwsłonecznego do stosowania miejscowego
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) † 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
JPS5788115A (en) * 1980-10-06 1982-06-01 Miles Lab Stable non-aqueous solution of tetracycline antibiotic salt
DE3320583A1 (de) † 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPS61189230A (ja) * 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd エトポシド製剤
GB8528959D0 (en) * 1985-11-25 1986-01-02 Leo Pharm Prod Ltd Chemical compounds
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
JPH0720866B2 (ja) † 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
JP2794022B2 (ja) † 1988-11-11 1998-09-03 三生製薬株式会社 ブナゾシン或いはその塩類含有経皮適用製剤
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
JPH03236317A (ja) † 1989-12-06 1991-10-22 Sansei Seiyaku Kk ドパミン誘導体含有経皮用製剤
US5733572A (en) † 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
EP0520119A1 (de) † 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
AU3136293A (en) † 1991-11-15 1993-06-15 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5314685A (en) † 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
AU6410494A (en) † 1993-03-17 1994-10-11 Alza Corporation Device for the transdermal administration of alprazolam
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
DE69401945T3 (de) † 1993-06-25 2004-09-02 Alza Corp., Palo Alto Einarbeitung eines poly-n-vinylamids in ein transdermales system
AU679794B2 (en) † 1993-09-29 1997-07-10 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutynin
CA2203566C (en) * 1994-10-24 2001-10-23 Yuko Hosokawa Percutaneously administration preparation
US5736159A (en) † 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
PT831826E (pt) * 1995-06-06 2003-02-28 Hoffmann La Roche Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
UA48973C2 (uk) † 1995-06-07 2002-09-16 Орто-Макнейл Фармасьютікалз Інк. Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
US6572879B1 (en) † 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5906830A (en) † 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5766620A (en) † 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
ES2259746T3 (es) † 1996-07-15 2006-10-16 Alza Corporation Nuevas formulaciones para la administracion transdermica de fluoxetina.
ES2191834T3 (es) † 1996-10-24 2003-09-16 Alza Corp Agentes que facilitan la permeacion y destinados para composiciones, dispositivos y procedimientos de aporte transdermico de medicamentos.
DE19646392A1 (de) † 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
PT949905E (pt) * 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
US20020039594A1 (en) † 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
SI9700186B (sl) † 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin

Also Published As

Publication number Publication date
HK1094528A1 (en) 2007-04-04
TW200730199A (en) 2007-08-16
DE60027272T2 (de) 2007-01-25
WO2000045790A3 (en) 2000-12-07
EP1666026B1 (en) 2011-12-21
PT1152749E (pt) 2006-08-31
KR100858856B1 (ko) 2008-09-17
EP1666026A2 (en) 2006-06-07
TWI292716B (en) 2008-01-21
PT1666026E (pt) 2012-03-15
NO20013861L (no) 2001-09-20
CY1119950T1 (el) 2018-12-12
JP2002536315A (ja) 2002-10-29
HUP0200202A3 (en) 2009-08-28
AU3481600A (en) 2000-08-25
DE60027272D1 (de) 2006-05-24
ES2261190T3 (es) 2006-11-16
KR20010101842A (ko) 2001-11-14
KR20080045300A (ko) 2008-05-22
CO5140096A1 (es) 2002-03-22
ES2379471T5 (es) 2015-05-26
HK1041451B (zh) 2006-12-01
HK1041451A1 (en) 2002-07-12
JP4861551B2 (ja) 2012-01-25
DK1666026T3 (da) 2012-04-10
AU775904B2 (en) 2004-08-19
EP1666026A3 (en) 2007-08-08
EP1666026B2 (en) 2015-02-25
NO20013861D0 (no) 2001-08-08
CA2361424A1 (en) 2000-08-10
NZ513441A (en) 2004-01-30
AR029613A1 (es) 2003-07-10
ZA200106443B (en) 2002-08-06
CA2361424C (en) 2009-04-28
ES2379471T3 (es) 2012-04-26
CN1232244C (zh) 2005-12-21
EP1152749B1 (en) 2006-04-12
WO2000045790A2 (en) 2000-08-10
DK1666026T4 (da) 2015-05-04
EP1152749A2 (en) 2001-11-14
IL144755A0 (en) 2002-06-30
ATE322889T1 (de) 2006-04-15
ATE537811T1 (de) 2012-01-15
CN1339962A (zh) 2002-03-13

Similar Documents

Publication Publication Date Title
HUP0200202A2 (hu) Stabilis, nemvizes egyfázisú, viszkózus vivőanyagok és ilyen vivőanyagokat hasznosító összetételek
DK0915898T3 (da) Krystalform I af clarithromycin
IL117144A0 (en) Pharmaceutical compositions containing nucleic acids
BR9908015A (pt) Composições que compreendem vìrus e métodos para concentração de preparações de vìrus
HUP0104037A2 (hu) Elsősorban progesztineknél és ösztrogéneknél alkalmazható hordozórendszer
EP1017411A4 (en) COMPOSITION PROVIDING REGULATED RELEASE OF HORMONE GNRH AND ITS ANALOGS
DK0717617T3 (da) Mikropartikler indeholdende aktive bestanddele og gas
CR7420A (es) Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
DK0412710T3 (da) Bæremediumsystemer til anvendelse i kosmetiske præparater
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
EP0990443A3 (en) Medicinal compositions
DE69022670D1 (de) Trägersystem für kosmetische Zubereitungen.
EA199900835A1 (ru) Стабильная частица в жидких композициях
GB8613481D0 (en) Translation of mrna
HUP0303295A2 (hu) Szilárd, vízben oldható, bőrre ható hatóanyagot tartalmazó, vízmentes izzadásgátló és dezodoráló készítmények
DE69906938D1 (de) Glococorticoid selektive entzündungshemmende mittel
PE20000143A1 (es) Composiciones de cremas antisudorales con eficacia antisudoral y de lavado mejorada
AP2001002054A0 (en) Use of biogenic estrogen sulfamates for hormone replacement therapy.
MXPA05010384A (es) Composiciones adherentes para el cuidado de la piel y articulos que tienen las composiciones adherentes para el cuidado de la piel colocadas encima.
AU3251799A (en) Device for releasing substances
HUP0204005A2 (hu) Pravastatin-nátrium új módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE355821T1 (de) Multiphasensystem
PT928192E (pt) Gel antimicotico com elevada libertacao de principio activo
HUP0101393A1 (hu) Redukáló körülményekre érzékeny transzfektáló kompozíciók, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees